🇺🇸 FDA

Intelligence Platform

Patents

Browse 837 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10316105

Anti-TIE2 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10306874

Non-human animals having a humanized lymphocyte-activation gene 3

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10285388

Non-human animals having a disruption in a C9ORF72 locus

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 14 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 09 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10278374

Genetically modified mice and engraftment

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 07 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10266588

Method of treating osteoarthritis with an antibody to NGF

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10266582

GPR156 variants and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10259870

Anti-ANGPTL8 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10261094

Competitive ligand binding assay for detecting neutralizing antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10253102

Antigen-binding proteins that activate the leptin receptor

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10251938

Angiopoietin-based interventions for treating cerebral malaria

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10246509

Restricted immunoglobulin heavy chain mice

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10233250

Human antibodies to the glucagon receptor and methods of use thereof for lowering blood gl

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10212923

Humanized dipeptidyl-peptidase IV (DPP4) animals

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10206379

Non-human animals having a humanized signal-regulatory protein gene

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10196613

Stem cells for modeling type 2 diabetes

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10189901

Methods for improving cardiac function by administering an antibody that activates APLNR

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10179819

Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and use

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10162933

High resolution allele identification

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 25 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10155811

APLNR modulators and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10137193

Methods for treating or preventing asthma by administering an IL-4R antagonist

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10130681

Use of a VEGF antagonist to treat angiogenic eye disorders

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10123518

Genetically modified non-human animals and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10125188

Human antibodies to respiratory syncytial virus F protein and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10111953

Methods for reducing remnant cholesterol and other lipoprotein fractions by administering

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted